Pandion Therapeutics Inc. Common Stock
PAND
PAND was delisted on the 31st of March, 2021.
48 hedge funds and large institutions have $158M invested in Pandion Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 14 closing their positions.
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
31% more capital invested
Capital invested by funds: $121M → $158M (+$36.9M)
8% less funds holding
Funds holding: 52 → 48 (-4)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.56M |
| 2 |
BlackRock
New York
|
+$3.96M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$3.88M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.78M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.16M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.98M |
| 3 |
Millennium Management
New York
|
-$2.48M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.66M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.15M |
PAND Hedge Fund Activity: Q4 2020 in Review
48 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Pandion Therapeutics Inc. Common Stock (PAND) for Q4 2020, worth a combined $158M — up 31% from $121M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PAND and 10 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 21 added.
The largest buyer was Citadel Advisors, adding an estimated $4.56M. The largest seller was Logos Global Management, exiting entirely with an estimated $5.16M sold.
- 48 institutional investors held Pandion Therapeutics Inc. Common Stock (PAND) as of Q4 2020, down from 52 in Q3 2020.
- Funds reported $158M of Pandion Therapeutics Inc. Common Stock stock for Q4 2020, up 31% quarter-over-quarter.
- 10 funds opened new Pandion Therapeutics Inc. Common Stock positions in Q4 2020 and 14 closed out, a net change of -4 holders.
- The largest Pandion Therapeutics Inc. Common Stock buyer in Q4 2020 was Citadel Advisors, an estimated $4.56M added.
- The largest Pandion Therapeutics Inc. Common Stock seller in Q4 2020 was Logos Global Management, an estimated $5.16M sold.
Based on aggregated 13F filings for Q4 2020.